VCP746

an adenosine A2B receptor agonist; structure in first source

Also Known As:

4-(5-amino-4-benzoyl-3-(3-(trifluoromethyl)phenyl)thiophen-2-yl)-N-(6-(9-(3,4-dihydroxy-5-(hydroxylmethyl)tetrahydrofuran-2-yl)-9H-purin-6-ylamino)hexyl)benzamide

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Christopoulos, Arthur: 5 articles (01/2022 - 01/2016)
2.	May, Lauren T: 5 articles (01/2022 - 01/2016)
3.	White, Paul J: 5 articles (01/2022 - 01/2016)
4.	Scammells, Peter J: 3 articles (01/2022 - 10/2016)
5.	Sexton, Patrick M: 2 articles (01/2021 - 01/2016)
6.	Baltos, Jo-Anne: 2 articles (10/2016 - 01/2016)
7.	Wang, Bing H: 2 articles (10/2016 - 10/2016)
8.	Awalt, Jon Kyle: 1 article (01/2022)
9.	Fyfe, Tim J: 1 article (01/2022)
10.	Jörg, Manuela: 1 article (01/2022)

Related Diseases

1.	Hypertrophy 10/01/2016 - "This study has shown that the novel A1 AR agonist, VCP746, is able to attenuate cardiac myocyte hypertrophy. " 10/01/2016 - "VCP746 significantly inhibited IL-1β-, TNF-α- and Ang II-stimulated NCM hypertrophy as determined by (3) H-leucine incorporation. " 10/01/2016 - "VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model."
2.	Bradycardia 10/01/2016 - "At the A1AR, VCP746 mediated cardioprotection in the absence of haemodynamic side effects such as bradycardia. " 01/01/2022 - "Previously, we demonstrated that the bitopic agonist VCP746 (1), consisting of an adenosine pharmacophore linked to an allosteric moiety, can stimulate cardioprotective A1R signaling effects in the absence of unwanted bradycardia. " 01/01/2016 - "In native systems, the atypical A1AR agonists VCP746 and capadenoson retain cytoprotective signaling in the absence of bradycardia, a phenomenon suggestive of biased agonism. "
3.	Myocardial Infarction 10/01/2016 - "As such, VCP746 is potentially useful as a pharmacological agent in attenuating cardiac remodelling, especially in the post-myocardial infarction setting, given its previously established cytoprotective properties."
4.	Heart Failure 01/01/2021 - "We compare this agent with the well-characterized, pan-adenosine receptor (AR) agonist NECA, capadenoson, and the A1R biased agonist VCP746, previously shown to be safe and cardioprotective in pre-clinical models of heart failure. "

Related Drugs and Biologics

1.	Purinergic P1 Receptors (Adenosine Receptor)
2.	capadenoson
3.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
4.	Leucine (L-Leucine)
5.	Adenosine (Adenocard)